Neurocrine Biosciences (NBIX) Long-Term Investments (2010 - 2026)

Neurocrine Biosciences has reported Long-Term Investments for 17 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 63.25% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 63.25% YoY), and the FY2025 full-year result was $1.1 billion, up 43.75% from the prior year.
• Long-Term Investments for Q1 2026 stood at $1.3 billion, up from $1.1 billion in the prior quarter.
• The five-year high for Long-Term Investments was $1.3 billion in Q1 2026, with the low at $244.6 million in Q1 2023.
• Historically, Long-Term Investments has averaged $655.3 million across 5 years, with a median of $643.9 million in 2024.
• Annual changes were most pronounced in 2023 — Long-Term Investments sank 54.79% — and 2024, when it surged 186.35%.
• Neurocrine Biosciences' Long-Term Investments stood at $299.4 million in 2022, then soared by 129.63% to $687.5 million in 2023, then grew by 7.56% to $739.5 million in 2024, then soared by 43.75% to $1.1 billion in 2025, then rose by 25.21% to $1.3 billion in 2026.
• The last three Long-Term Investments figures came in at $1.3 billion (Q1 2026), $1.1 billion (Q4 2025), and $998.5 million (Q3 2025), per Business Quant data.